Stock in downward trend since 9th November. Found support at 77-80p range. Showing signs of reversal with stochastic coming out of oversold. Target to trade would be the 50sma or resitance line at 140p.
Prudent Drug Discovery Company
Low market cap ( appox £13m at time of writing ).
Issues shares very rarely ( last placing nearly four years ago ).
Has material interest in its work from larger partners ( Pharmaxis ).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains...